Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Andy Boshier"'
Autor:
Joseph K. Park, Troy E. Barger, June Kim, David J. Kuter, Vibha Jawa, Andy Boshier, Daniel T. Mytych
Publikováno v:
British Journal of Haematology
Summary Antibodies to first‐generation recombinant thrombopoietin (TPO) neutralized endogenous TPO and caused thrombocytopenia in some healthy subjects and chemotherapy patients. The second‐generation TPO receptor agonist romiplostim, having no s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4242a0d19611b4c500a82f239b3cc500
https://pubmed.ncbi.nlm.nih.gov/32311075
https://pubmed.ncbi.nlm.nih.gov/32311075
Autor:
Louise Taylor, Anouchka Seesaghur, Martin R. Schipperus, Georgia Kaiafa, Georg Kreuzbauer, Sally Wetten, Andy Boshier
Publikováno v:
Drug Safety
Introduction Romiplostim is a subcutaneously administered thrombopoietin-receptor agonist approved in the European Union for self-administration (or administration by a caregiver) in selected adult patients with chronic primary immune thrombocytopeni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c613ea46a4c680442216f3f1de0293d
https://doi.org/10.1007/s40264-018-0723-6
https://doi.org/10.1007/s40264-018-0723-6
Autor:
Andy Boshier, Joseph K. Park, David J. Kuter, June Kim, Troy E. Barger, Vibha Jawa, Daniel T. Mytych
Publikováno v:
Blood. 132:2427-2427
Background: Romiplostim (Nplate®) is a thrombopoietin (TPO) receptor agonist approved for the treatment of adult chronic immune thrombocytopenia (ITP). The formation of antibodies (Abs) against romiplostim may lead to a loss of response, and a theor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6cad3e89f6bed71830dd5fae56c1dc1f
https://doi.org/10.1182/blood-2018-99-113484
https://doi.org/10.1182/blood-2018-99-113484
Autor:
Anouchka Seesaghur, Andy Boshier, Sally Wetten, Georgia Kaiafa, James Bennett, Martin R. Schipperus, Georg Kreuzbauer, Louise Taylor
Publikováno v:
Blood. 128:4918-4918
Background: Romiplostim is a subcutaneously administered thrombopoietin-receptor agonist approved for use in the EU for adult patients with chronic immune thrombocytopenia (ITP) refractory to other treatments. Initially approved for administration by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8ed948c96ca809c4bd7580808a00ee79
https://doi.org/10.1182/blood.v128.22.4918.4918
https://doi.org/10.1182/blood.v128.22.4918.4918
Autor:
Mytych, Daniel T., Park, Joseph K., Kim, June, Barger, Troy E., Boshier, Andy, Jawa, Vibha, Kuter, David J.
Publikováno v:
British Journal of Haematology; Sep2020, Vol. 190 Issue 6, p923-932, 10p
Autor:
Schipperus, Martin, Kaiafa, Georgia, Taylor, Louise, Wetten, Sally, Kreuzbauer, Georg, Boshier, Andy, Seesaghur, Anouchka
Publikováno v:
Drug Safety; Jan2019, Vol. 42 Issue 1, p77-83, 7p